NCT05165771View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

March 31, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

GS-5718

Tablets administered orally

DRUG

GS-5718

Tablets administered orally

DRUG

Placebo to match GS-5718

Tablets administered orally

DRUG

Tofacitinib 5 mg

Tablets administered orally

DRUG

Placebo to match Tofacitinib

Tablets administered orally

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT05165771 - Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment | Biotech Hunter | Biotech Hunter